VIRX Stock Summary and Trading Ideas (Viracta Therapeutics | NASDAQ:VIRX)

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Viracta Therapeutics trades on the NASDAQ stock market under the symbol VIRX.

As of January 31, 2025, VIRX stock price declined to $0.15 with 342,654 million shares trading.

VIRX has a beta of -0.36, meaning it tends to be less sensitive to market movements. VIRX has a correlation of 0.00 to the broad based SPY ETF.

VIRX has a market cap of $5.96 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, VIRX traded as high as $5.75 and as low as $.13.

The top ETF exchange traded funds that VIRX belongs to (by Net Assets): VXF.

VIRX has underperformed the market in the last year with a price return of -70.6% while the SPY ETF gained +25.5%. VIRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.8% and -16.6%, respectively, while the SPY returned +5.4% and +3.0%, respectively.

VIRX support price is $.14 and resistance is $.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIRX shares will trade within this expected range on the day.